PT2802652T - Enzimas de clostridium histolyticum - Google Patents

Enzimas de clostridium histolyticum

Info

Publication number
PT2802652T
PT2802652T PT13736040T PT13736040T PT2802652T PT 2802652 T PT2802652 T PT 2802652T PT 13736040 T PT13736040 T PT 13736040T PT 13736040 T PT13736040 T PT 13736040T PT 2802652 T PT2802652 T PT 2802652T
Authority
PT
Portugal
Prior art keywords
clostridium histolyticum
enzyme
histolyticum enzyme
clostridium
histolyticum
Prior art date
Application number
PT13736040T
Other languages
English (en)
Inventor
K Herber Wayne
Original Assignee
Endo Global Ventures
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endo Global Ventures filed Critical Endo Global Ventures
Publication of PT2802652T publication Critical patent/PT2802652T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24003—Microbial collagenase (3.4.24.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24027—Thermolysin (3.4.24.27)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96402—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from non-mammals
    • G01N2333/96405—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from non-mammals in general
    • G01N2333/96408—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from non-mammals in general with EC number
    • G01N2333/96419—Metalloendopeptidases (3.4.24)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
PT13736040T 2012-01-12 2013-01-10 Enzimas de clostridium histolyticum PT2802652T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261585909P 2012-01-12 2012-01-12

Publications (1)

Publication Number Publication Date
PT2802652T true PT2802652T (pt) 2019-09-10

Family

ID=48782075

Family Applications (2)

Application Number Title Priority Date Filing Date
PT13736040T PT2802652T (pt) 2012-01-12 2013-01-10 Enzimas de clostridium histolyticum
PT191741826T PT3584317T (pt) 2012-01-12 2013-01-10 Enzima de clostridium histolyticum

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT191741826T PT3584317T (pt) 2012-01-12 2013-01-10 Enzima de clostridium histolyticum

Country Status (13)

Country Link
US (6) US9757435B2 (pt)
EP (4) EP4276180A3 (pt)
JP (5) JP6263755B2 (pt)
AU (6) AU2013208028B2 (pt)
BR (1) BR112014017229B1 (pt)
CA (2) CA2861033C (pt)
DK (2) DK2802652T3 (pt)
ES (3) ES2740499T3 (pt)
HU (2) HUE057423T2 (pt)
MX (1) MX351448B (pt)
NZ (5) NZ750379A (pt)
PT (2) PT2802652T (pt)
WO (1) WO2013106510A2 (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2859412C (en) * 2011-12-14 2021-05-25 The Board Of Trustees Of The University Of Arkansas Delivery of therapeutic agents using bacterial collagen-binding polypeptide segments
EP4276180A3 (en) * 2012-01-12 2024-01-10 Endo Global Ventures Clostridium histolyticum enzyme
RU2540919C1 (ru) * 2013-09-27 2015-02-10 Государственное автономное учреждение здравоохранения "Республиканская клиническая больница Министерства здравоохранения Республики Татарстан" Способ безоперационного лечения контрактуры дюпюитрена iii-iv степени тяжести
PT107276B (pt) * 2013-11-07 2018-06-07 Univ Aveiro Método para produção de colagenase recombinante para digestão de colagénios
WO2017074257A1 (en) * 2015-10-26 2017-05-04 Nanyang Technological University Non-viable derivatives of clostridium sporogenes as anti-cancer therapeutic agents
EP3551230A1 (en) * 2016-12-08 2019-10-16 CureVac AG Rna for treatment or prophylaxis of a liver disease
US11542490B2 (en) 2016-12-08 2023-01-03 CureVac SE RNAs for wound healing
JP7397440B2 (ja) 2017-02-10 2023-12-13 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ アーカンソー コラーゲン結合薬剤組成物およびその使用方法
AU2018226820B2 (en) 2017-03-01 2022-12-08 Endo Ventures Limited Apparatus and method for assessing and treating cellulite
BR112019020394A2 (pt) 2017-03-28 2020-04-22 Endo Ventures Ltd método melhorado de produção de colagenase
CZ308157B6 (cs) * 2017-09-13 2020-01-29 MB PHARMA s.r.o. Kmen bakterie Clostridium histolyticum, kolagenáza připravená s použitím tohoto kmene a její použití
WO2020021332A2 (en) 2018-07-12 2020-01-30 Endo Global Aesthetics Limited Injection techniques for the treatment of cellulite
WO2020021330A2 (en) 2018-07-12 2020-01-30 Endo Global Aesthetics Limited Injection techniques for the treatment of cellulite
CA3112437A1 (en) 2018-09-18 2020-03-26 Endo Global Aesthetics Limited Compositions and methods for treating cellulite
CN109355222B (zh) * 2018-11-06 2020-06-02 上海交通大学 对水稻白叶枯病菌具有拮抗作用的芽孢杆菌及分离与应用
US20220305094A1 (en) 2019-01-06 2022-09-29 Endo Global Aesthetics Limited Collagenase formulations and methods of producing the same
WO2020164721A1 (de) * 2019-02-14 2020-08-20 Nordmark Arzneimittel Gmbh & Co. Kg Chromatographische aufreinigung von wenigstens einem enzym, ausgesucht aus der gruppe bestehend aus kollagenase typ i, neutrale protease und clostripain
CN113025599B (zh) * 2021-04-02 2023-09-12 重庆科润生物医药研发有限公司 一种重组溶组织梭菌i型胶原酶及其制备方法和应用
CN112941058B (zh) * 2021-04-02 2023-12-05 重庆科润生物医药研发有限公司 一种重组溶组织梭菌ii型胶原酶及其制备方法和应用
WO2023112020A1 (en) * 2021-12-14 2023-06-22 Ramot At Tel Aviv University Ltd. Modified recombinant collagenase, compositions comprising the same and uses thereof in dental related procedures

Family Cites Families (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3821364A (en) * 1966-07-08 1974-06-28 Advance Biofactures Corp Process of producing collagenase
JPS5662229A (en) 1979-10-25 1981-05-28 Asahi Glass Co Ltd Electro-optical dimming panel
US4338300A (en) 1981-02-05 1982-07-06 The Regents Of The University Of California Use of purified clostridial collangenase in the treatment of Peyronie's disease
EP0115974B1 (fr) 1983-01-05 1988-09-07 Institut Pasteur Préparation à activité collagénolytique ayant une activité élevée et compositions pharmaceutiques la contenant
US4645668A (en) 1983-08-04 1987-02-24 Biospecifics, Nv Method for the prevention and treatment of scars with enzymes
US4524065A (en) 1983-08-04 1985-06-18 Bio-Specifics N.V. Method for the prevention and treatment of scars with enzymes
US4542065A (en) 1984-05-21 1985-09-17 Ppg Industries, Inc. Chemically treated glass fibers and strands and dispersed products thereof
JPS61289885A (ja) 1985-06-14 1986-12-19 Nitta Zerachin Kk コラゲナ−ゼおよびコラゲナ−ゼの製造方法
JP2898022B2 (ja) 1989-09-05 1999-05-31 株式会社ニッピ コラーゲン分解酵素の製造方法
US5252461A (en) 1990-05-01 1993-10-12 The Regents Of The Univ. Of California Mixed immunoglobulins for detection of rheumatoid factors
CA2047306A1 (en) 1990-07-23 1992-01-24 Milan Holjevac Mutant bacterium clostridium histolyticum, a process for the obtaining thereof, and its use in the production of clostripain-free collagenase
US5393792A (en) 1991-11-20 1995-02-28 Advance Biofactures Of Curacao, N.V. High dosage topical forms of collagenase
US5462739A (en) 1991-11-21 1995-10-31 Yeda Research And Development Co., Ltd. Microdelivery device and method for enhanced drug administration to the eye
US5256140A (en) 1992-03-27 1993-10-26 Fallien Cosmeceuticals, Ltd. Composition for levelling skin
EP0654084A4 (en) * 1992-06-22 1996-07-03 Trigen Inc MOLECULAR CLONING OF GENES RESPONSIBLE FOR THE PRODUCTION OF COLLAGENASE FROM -i (CLOSTRIDIUM HISTOLYTICUM).
WO1994016086A1 (en) 1992-12-30 1994-07-21 Bioteknologisk Institut Recombinant lactic acid bacterium containing an inserted promoter and method of constructing same
JP3186881B2 (ja) 1993-02-18 2001-07-11 倉敷紡績株式会社 肝細胞の分離方法
US5332503A (en) 1993-04-16 1994-07-26 Baxter International Inc. Process for purifying collagenase
US5514340A (en) 1994-01-24 1996-05-07 Magnetix Biotechnology, Inc. Device for separating magnetically labelled cells
JP3028852B2 (ja) 1994-06-24 2000-04-04 ロシュ ダイアグノスティックス コーポレーション ヒストリチクス菌から得られるコラゲナーゼおよび２つの他のプロテアーゼの精製混合物
US5589171A (en) 1994-08-22 1996-12-31 Advance Biofactures Of Curacao Treatment of Dupuytren's disease with collagenase
CA2158822C (en) 1994-09-27 2008-12-23 Kusuki Nishioka Therapeutic agent for rheumatic disease
US6958150B2 (en) 1994-12-15 2005-10-25 Advance Biofactures Of Curacao, N.V. Reduction of adipose tissue
BR9607143A (pt) 1995-03-16 1997-11-25 Knoll Ag Enzima ibtenível de clostridium histolyticum mistura de enzimas uso da mistura uso de enzimas colagenase hp na forma pura colagenase az na forma pura e elastase na forma pura
US5705170A (en) 1995-10-24 1998-01-06 Plantech International, Inc. Herbal cellulite treatments
US5989888A (en) 1996-01-24 1999-11-23 Roche Diagnostics Corporation Purified mixture of collagenase I, collagenase II and two other proteases
ATE226637T1 (de) 1996-09-06 2002-11-15 Bioteknologisk Inst Milchsäurebakterielles regulierbares expressionssystem
EP0941311B1 (de) * 1996-11-19 2004-07-28 Boehringer Mannheim Gmbh Rekombinante collagenase typ i aus clostridium histolyticum und ihre verwendung zur isolierung von zellen und zellverbänden
US5830741A (en) 1996-12-06 1998-11-03 Boehringer Mannheim Corporation Composition for tissue dissociation containing collagenase I and II from clostridium histolyticum and a neutral protease
US5753785A (en) 1996-12-16 1998-05-19 Fina Technology, Inc. Production of E-B copolymers with a single metallocene catalyst and a single monomer
US6086872A (en) 1997-03-27 2000-07-11 Advance Biofactures Of Curacao, Nv Amelioration of dupuytren's disease
JPH10262658A (ja) 1997-03-28 1998-10-06 Kikkoman Corp ザルコシン・オキシダーゼの結晶、その製造方法及び三次元構造
TR200001789T2 (tr) 1997-10-03 2000-10-23 Lavipharm Laboratories, Inc. Prolamin-bitki kutuplu lipit kompozisyonu, bunun hazırlama ve uygulama metodu
GB9724802D0 (en) 1997-11-24 1998-01-21 Unilever Plc Antiperspirant or deodorant compoistions
US20020036328A1 (en) 1998-11-16 2002-03-28 William R. Richards, Jr. Offset drain fermi-threshold field effect transistors
FR2788682B1 (fr) 1999-01-26 2001-04-06 Seb Sa Dispositif de thermographie
US6022539A (en) 1999-06-03 2000-02-08 Advance Biofactures Of Curacao Amelioration of peyronie's disease
RU2180002C2 (ru) 1999-08-16 2002-02-27 Пермское научно-производственное объединение "Биомед" Способ получения коллагеназы
JP2003507400A (ja) 1999-08-20 2003-02-25 ハワード ムラード セリュライトの出現を軽減する医薬組成物及び方法
US6280993B1 (en) * 1999-08-24 2001-08-28 Ichiro Yamato Gene encoding class I collagenase
ITMI991894A1 (it) 1999-09-09 2001-03-09 Carlo Ghisalberti Acido linoleico coniugato e trigliceride nuovi metodi di sintesi e d'uso
PT1923068E (pt) 1999-09-24 2011-07-29 Proteon Therapeutics Inc Sistema e métodos para a abertura de condutas biológicas obstruídas
US7811250B1 (en) 2000-02-04 2010-10-12 Boston Scientific Scimed, Inc. Fluid injectable single operator exchange catheters and methods of use
US20030026844A1 (en) 2000-04-18 2003-02-06 Hee-Yong Lee Injectable sustained release pharmaceutical composition and processes for preparing the same
JP4399158B2 (ja) 2000-10-20 2010-01-13 バイオニアー エイ／エス 乳酸菌における異種遺伝子産物の製造のための改良発酵法
AU3104102A (en) 2000-12-18 2002-07-01 Univ Texas Local regional chemotherapy and radiotherapy using in situ hydrogel
AU2002251831A1 (en) 2001-01-30 2002-08-12 The Regents Of The University Of Michigan Methods for sustained release local delivery of drugs for ablation of unwanted tissue
WO2003004628A2 (de) 2001-07-02 2003-01-16 Nordmark Arzneinmittel Gmbh & Co. Kg Verfahren zur aufreinigung eines enzyms und hiernach hergestelltes, aufgereinigtes enzym sowie verwendung des enzyms
GB0124124D0 (en) 2001-10-08 2001-11-28 Medical Res Council Methods of treatment
JP2003284553A (ja) 2002-03-28 2003-10-07 Seikagaku Kogyo Co Ltd 生理活性タンパク質
CA2490725A1 (en) 2002-06-25 2003-12-31 Ultrashape Inc. Devices and methodologies useful in body aesthetics
EP1433845A1 (en) * 2002-12-23 2004-06-30 Georg-August-Universität Clostridium tetani collagenase and uses thereof
EP1462519A1 (en) 2003-03-24 2004-09-29 Boehringer Ingelheim Austria GmbH Method and devices for producing biomolecules
JP4205496B2 (ja) 2003-06-19 2009-01-07 三菱化学株式会社 新規カルボニル還元酵素及びこれをコードするｄｎａ、ならびにこれらを利用した光学活性アルコールの製造方法
EP1709194A4 (en) 2003-12-17 2007-07-25 Univ Columbia ADMINISTRATION OF DNA OR RNA THROUGH LACUNAR JUNCTION OF HOST CELLS TO TARGET CELLS AND CELL-BASED DELIVERY SYSTEM FOR ANTISENSE OR ARNS
EP2532742B1 (en) 2004-01-30 2018-08-08 Shire Pharmaceuticals Ireland Limited Recombinant arylsulfatase A for reducing galatosyl sulphatide levels in a subject
CA2562024C (en) 2004-04-07 2014-05-27 Rinat Neuroscience Corp. Methods for treating bone cancer pain by administering a nerve growth factor antagonist
US7754230B2 (en) 2004-05-19 2010-07-13 The Regents Of The University Of California Methods and related compositions for reduction of fat
TR201802446T4 (tr) 2004-05-19 2018-03-21 Los Angeles Biomedical Res Inst Harbor Ucla Medical Ct Sodyum deoksikolat içeren enjeksiyonluk bileşim.
US7355027B2 (en) 2004-06-16 2008-04-08 Dynport Vaccine Company Llc Bacillus anthracis protective antigen
PT1781697E (pt) 2004-07-07 2009-06-25 Lundbeck & Co As H Nova epo carbamilada e método para a sua produção
CA2572765C (en) 2004-07-08 2013-05-21 Amgen Inc. Compound having improved bioefficiency when administered in a multidose regimen
US20060020448A1 (en) 2004-07-21 2006-01-26 Microsoft Corporation Method and apparatus for capitalizing text using maximum entropy
JP4923131B2 (ja) 2004-08-30 2012-04-25 株式会社リコー ログ収集システム、ログ収集装置およびログ収集プログラム
JP4976131B2 (ja) 2004-08-30 2012-07-18 株式会社ダイセル ポリグリセリンモノエーテル及びその製造方法
US20150025420A1 (en) 2004-10-06 2015-01-22 Guided Therapy Systems, Llc Ultrasound treatment device and methods of use
DE102004060075A1 (de) 2004-12-14 2006-07-06 Merck Patent Gmbh Verfahren zur Herstellung von Onium-Salzen mit Dialkylphosphat-, Dialkylphosphinat oder (O-Alkyl)-alkyl- oder Alkyl-phosphonat-Anionen mit geringem Halogenid-Gehalt
US20070224184A1 (en) 2006-02-22 2007-09-27 The Research Foundation Of The State University Of New York Method for treating cellulite
PT1846022E (pt) 2005-01-21 2015-09-03 Univ New York State Res Found Métodos para o tratamento de capsulite adesiva
US7854929B2 (en) 2005-01-21 2010-12-21 The Research Foundation Of State University Of New York Method for treating lateral epicondylitis using collagenase
JP2006254876A (ja) 2005-03-18 2006-09-28 Hokkaido Univ Ｌ−トリプトファン製造法
US20060241673A1 (en) 2005-04-21 2006-10-26 Zadini Filiberto P Subcision device
US20060251581A1 (en) 2005-05-09 2006-11-09 Mcintyre Jon T Method for treatment of uterine fibroid tumors
US20070003541A1 (en) 2005-07-01 2007-01-04 Rodolfo Faudoa Methods and compositions for therapeutics
ITPD20050207A1 (it) 2005-07-07 2007-01-08 Fidia Farmaceutici Nuove composizioni farmaceutiche contenenti acido ialuronico e collagenas nel trattamento topico di ferite, ustioni ed ulcere
US20070031482A1 (en) 2005-08-02 2007-02-08 Ceramoptec Industries, Ind. PDT treatment method for cellulites and cosmetic use
US7811560B2 (en) 2006-01-30 2010-10-12 Auxilium Us Holdings, Llc Compositions and methods for treating collagen-mediated diseases
WO2007100590A2 (en) 2006-02-22 2007-09-07 Auxilium Pharmaceuticals, Inc. Methods for treating cellulite
EP2001561A2 (en) 2006-03-31 2008-12-17 DSMIP Assets B.V. Novel use of compounds and combinations of compunds for improving the physical appearance
WO2008100833A2 (en) 2007-02-13 2008-08-21 Auxilium International Holdings, Inc. Production of recombinant collagenases colg and colh in escherichia coli
US8617543B2 (en) 2007-02-14 2013-12-31 Yolare Pharmaceuticals, LLC Modified mutant collagenase and its use in fat melting and in scar reduction
CN101677912B (zh) 2007-05-11 2013-06-12 希格马托制药工业公司 可用于递送化妆品活性成分的凝胶
US9987221B2 (en) 2007-08-23 2018-06-05 Boston Scientific Scimed, Inc. Injectable hydrogel compositions
KR101633612B1 (ko) 2007-10-26 2016-06-27 코닌클리케 필립스 엔.브이. 광각 선택 광 검출기 장치
WO2009059379A1 (en) 2007-11-07 2009-05-14 Dynamic Microbials Limited Antimicrobial compositions, formulations and uses thereof
US20100159564A1 (en) * 2007-11-30 2010-06-24 Dwulet Francis E Protease resistant recombinant bacterial collagenases
ES2388219T3 (es) 2008-06-02 2012-10-10 F. Hoffmann-La Roche Ag Purificación mejorada de colagenasas a partir de un cultivo líquido de Clostridium histolyticum
US8236356B2 (en) 2008-06-11 2012-08-07 Roche Diagnostics Operations, Inc. Growth medium for Clostridium histolyticum
CN102105133B (zh) 2008-07-21 2015-06-17 奥德纳米有限公司 控制释放型耳结构调节和先天性免疫系统调节组合物以及治疗耳部病症的方法
US8380531B2 (en) 2008-07-25 2013-02-19 Invivodata, Inc. Clinical trial endpoint development process
US20110160617A9 (en) 2008-10-22 2011-06-30 Allergan, Inc. Clinical assessment scales and methods
BRPI0921679A2 (pt) 2008-11-11 2016-02-16 Sigma Tau Ind Farmaceuti composto útil para tratar celulite
DK2363461T3 (en) * 2008-11-19 2015-03-02 Meiji Seika Pharma Co Ltd Fusion collagenase associated with affinity tags, and process for its preparation
IT1397646B1 (it) * 2009-12-15 2013-01-18 Seidita Collagenasi ricombinanti di c. histolyticum e metodo per la loro produzione.
US9132199B2 (en) 2010-03-05 2015-09-15 University of Pittsburgh—of the Commonwealth System of Higher Education Reverse thermal gels and uses therefor
US20130195828A1 (en) 2010-04-14 2013-08-01 Northwestern University Pharmaceutical Compositions and Methods for Digesting Atherosclerotic Plaques
US20130217789A1 (en) 2010-09-03 2013-08-22 North Carolina Central University Biodegradable liquogel and ph sensitive nanocarriers
ES2385239B1 (es) * 2010-09-30 2013-06-19 Proteos Biotech S.L.U. Uso de colagenasa g recombinante, colagenasa h recombinante y pz-peptidasa recombinante para el tratamiento de enfermedades que cursan con alteraciones del colágeno.
WO2012112940A1 (en) 2011-02-18 2012-08-23 Kythera Biopharmaceuticals, Inc. Treatment of submental fat
US10119131B2 (en) 2011-03-16 2018-11-06 Biospecifics Technologies Corp. Compositions and methods for producing clostridial collagenases
TWI461214B (zh) 2011-06-13 2014-11-21 Univ Chang Gung Biodegradable water-sensitive glue, a drug delivery system as a carrier thereof, and a pharmaceutical composition for the treatment and / or prevention of eye diseases
WO2013059263A1 (en) 2011-10-17 2013-04-25 Sound Surgical Technologies, Llc Ultrasonic probe for treating cellulite
BR112014009785B1 (pt) 2011-10-21 2020-06-30 Auxilium International Holdings, Inc. método cosmético para tratar ou reduzir panniculopatia fibrosclerótica edematória (pef)
EP4276180A3 (en) 2012-01-12 2024-01-10 Endo Global Ventures Clostridium histolyticum enzyme
CN104603616B (zh) 2012-09-07 2017-03-08 株式会社资生堂 使用纤蛋白‑3和/或肌聚糖γ作为指标评价脂肪团的方法和评价脂肪团有效药物的方法
CA2905756C (en) 2013-03-15 2016-11-29 Mary Kay Inc. Cosmetic compositions for reducing the appearance of cellulite or improving skin texture
DK2968484T3 (da) 2013-03-15 2021-02-22 Biospecifics Tech Corporation Behandlingsfremgangsmåde og produkt til uterus fibromer, som anvender oprenset kollagenase
US20160000890A1 (en) 2013-03-15 2016-01-07 Biospecifics Technologies Corp. Thermosensitive hydrogel collagenase formulations
CN103751102A (zh) 2014-01-15 2014-04-30 上海交通大学 一种胶原酶温敏水凝胶及其制备方法和应用
KR101896087B1 (ko) 2014-06-27 2018-09-06 주식회사 메디톡스 지방 감소를 위한 담즙산 및 염의 방법 및 조성물
CA3013776A1 (en) 2016-02-08 2017-08-17 OutcomeMD, Inc. Determining a wellness, improvement, or effectiveness score
WO2018077825A1 (en) 2016-10-28 2018-05-03 Merz Pharma Gmbh & Co. Kgaa Treatment of gynoid lipodystrophy
AU2018226820B2 (en) 2017-03-01 2022-12-08 Endo Ventures Limited Apparatus and method for assessing and treating cellulite
BR112019020394A2 (pt) 2017-03-28 2020-04-22 Endo Ventures Ltd método melhorado de produção de colagenase

Also Published As

Publication number Publication date
US20240269245A1 (en) 2024-08-15
AU2016208384C1 (en) 2023-10-05
AU2013208028B2 (en) 2016-04-28
US20230416717A1 (en) 2023-12-28
EP4015627A1 (en) 2022-06-22
EP4015627B1 (en) 2023-09-27
AU2023229488A1 (en) 2023-09-28
JP2020188810A (ja) 2020-11-26
JP2018075011A (ja) 2018-05-17
JP6752309B2 (ja) 2020-09-09
NZ733709A (en) 2022-10-28
AU2016208384A1 (en) 2016-08-11
JP7354197B2 (ja) 2023-10-02
EP4276180A2 (en) 2023-11-15
DK3584317T3 (en) 2022-01-03
CA2970639C (en) 2022-04-26
US20180055918A1 (en) 2018-03-01
JP2022023041A (ja) 2022-02-07
BR112014017229A8 (pt) 2017-07-04
ES2904884T3 (es) 2022-04-06
AU2021221653B2 (en) 2023-10-05
AU2013208028A1 (en) 2014-08-07
AU2016208378A1 (en) 2016-08-18
CA2861033C (en) 2017-07-25
EP3584317A1 (en) 2019-12-25
EP2802652B1 (en) 2019-06-05
JP6947888B2 (ja) 2021-10-13
US11975054B2 (en) 2024-05-07
ES2968836T3 (es) 2024-05-14
NZ750379A (en) 2022-10-28
NZ718173A (en) 2017-09-29
NZ627372A (en) 2016-04-29
JP2019103505A (ja) 2019-06-27
AU2019200192A1 (en) 2019-04-04
US9757435B2 (en) 2017-09-12
JP6496386B2 (ja) 2019-04-03
PT3584317T (pt) 2022-01-26
US20240252602A1 (en) 2024-08-01
US10603365B2 (en) 2020-03-31
US20200206326A1 (en) 2020-07-02
EP3584317B1 (en) 2021-11-24
AU2019200192B2 (en) 2021-07-01
JP6263755B2 (ja) 2018-01-24
CA2861033A1 (en) 2013-07-18
US20150010532A1 (en) 2015-01-08
EP2802652A2 (en) 2014-11-19
EP4276180A3 (en) 2024-01-10
AU2016208384B2 (en) 2018-09-13
WO2013106510A3 (en) 2013-10-03
ES2740499T3 (es) 2020-02-05
AU2016208378B2 (en) 2018-10-11
HUE046160T2 (hu) 2020-02-28
BR112014017229B1 (pt) 2022-05-17
NZ766918A (en) 2023-03-31
CA2970639A1 (en) 2013-07-18
HUE057423T2 (hu) 2022-05-28
WO2013106510A2 (en) 2013-07-18
DK2802652T3 (da) 2019-07-15
JP2015506176A (ja) 2015-03-02
MX351448B (es) 2017-10-16
BR112014017229A2 (pt) 2017-06-13
US11879141B2 (en) 2024-01-23
DK3584317T5 (da) 2022-01-17
EP2802652A4 (en) 2015-10-14
AU2021221653A1 (en) 2021-09-23
MX2014008441A (es) 2015-03-13

Similar Documents

Publication Publication Date Title
PT2802652T (pt) Enzimas de clostridium histolyticum
ZA201600633B (en) Variant enzymes
HK1207880A1 (en) Improved enzyme variants
EP2866024A4 (en) ENZYMATIC ELECTRODE
EP2751265A4 (en) NEW CELLOBIOHYDROLASES
ZA201500911B (en) Enzymes
EP2880050A4 (en) NOVEL ENZYMES, ENZYME COMPONENTS AND USES THEREOF
EP2866025A4 (en) ENZYMATIC ELECTRODE
HK1198445A1 (en) On-column enzymatic cleavage
HK1216999A1 (zh) 針對艱難梭菌的抗體
GB201214938D0 (en) Alternative oxidase
IL237172A0 (en) פוליפפטידים של clostridium difficile כתרכיבים
GB201207018D0 (en) Enzymes
EP2995681A4 (en) NOVEL DNA COLUMN ENZYME
ZA201400850B (en) Enzyme system
HK1211323A1 (en) Dual enzymatic amplification
GB201209420D0 (en) Prognostic gene
GB201211978D0 (en) Enzyme
EP2818559A4 (en) ENZYME TEST PROCEDURE
GB201223308D0 (en) Enzyme inhibitors
EP2970932A4 (en) ENZYMES WITH PULLULANASE ACTIVITY
GB201207952D0 (en) Restriction enzymes
GB201215883D0 (en) Enzyme inhibition
GB201215856D0 (en) Enzyme inhibition
GB201318464D0 (en) Modified enzymes